This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Biston, M.-C. Articles by Balosso, J. Search for Related Content PubMed PubMed Citation Articles by Biston, M.-C. Articles by Balosso, J. Related Collections Therapeutics and Targets Therapeutics and Targets: Drug Mechanisms and Resistance

Cure of Fisher Rats Bearing Radioresistant F98 Glioma Treated with cis-Platinum and Irradiated with Monochromatic Synchrotron X-Rays

¹ U647 Institut National de la Santé et de la Recherche Médicale "Rayonnement Synchrotron et Recherche Médicale," ID17 Medical Beamline and ² ID22 Beamline, European Synchrotron Radiation Facility, Grenoble, France, and ³ Unité Imagerie par Resonance Magnétique and ⁴ Département de Cancérologie et d’Hématologie, Centre Hospitalier Universitaire A. Michallon, Grenoble, France

High-grade gliomas are usually of poor prognosis, and conventional radiotherapy, even combined with chemotherapy, still fails to improve the survival of patients. Here, we propose an innovative therapeutic approach combining synchrotron radiation with cis-diamminedichloroplatinum (II) (CDDP). As suggested previously, monochromatic synchrotron irradiation of CDDP at 78.8 keV, just above the 78.4 keV platinum absorption K-edge, leads to an enhanced photoelectric effect and an increased local toxicity. To select a particular radiation energy that could provide supra-additive effect, we used pulsed-field gel electrophoresis to assess yields of DNA double-strand breaks induced in rat F98 glioma cells after CDDP treatment combined with synchrotron X-rays. Thereafter, intracerebral CDDP injection combined with synchrotron X-rays was applied to Fisher rats bearing F98 glioma. CDDP concentrations were mapped by synchrotron X-ray microfluorescence. An extra number of more slowly repaired double strand breaks were observed when irradiating CDDP-treated F98 cells at 78.8 keV. In vivo treatments were then performed with different radiation doses and CDDP concentrations. All cell inoculations in rat brain resulted in tumor development, and tumor presence was controlled by computed tomography. Among all of the conditions tested, the combination of 3 µg of CDDP with 15 Gy resulted in the largest median survival time (206 days). After 1 year, about 34% of treated rats were still alive. This preclinical finding, validated by molecular analysis, represents the most protracted survival reported with this radioresistant glioma model and demonstrates the interest in powerful monochromatic X-ray sources as new tools for cancer treatments.

This article has been cited by other articles:

				J. Rousseau, C. Boudou, R. F. Barth, J. Balosso, F. Esteve, and H. Elleaume Enhanced Survival and Cure of F98 Glioma Bearing Rats following Intracerebral Delivery of Carboplatin in Combination with Photon Irradiation Clin. Cancer Res., September 1, 2007; 13(17): 5195 - 5201. [Abstract] [Full Text] [PDF]

				F. A. Dilmanian, Z. Zhong, T. Bacarian, H. Benveniste, P. Romanelli, R. Wang, J. Welwart, T. Yuasa, E. M. Rosen, and D. J. Anschel Interlaced x-ray microplanar beams: A radiosurgery approach with clinical potential PNAS, June 20, 2006; 103(25): 9709 - 9714. [Abstract] [Full Text] [PDF]

				G. De Stasio, D. Rajesh, J. M. Ford, M. J. Daniels, R. J. Erhardt, B. H. Frazer, T. Tyliszczak, M. K. Gilles, R. L. Conhaim, S. P. Howard, et al. Motexafin-Gadolinium Taken Up In vitro by at Least 90% of Glioblastoma Cell Nuclei Clin. Cancer Res., January 1, 2006; 12(1): 206 - 213. [Abstract] [Full Text] [PDF]

				S. Corde, J.-F. Adam, M.-C. Biston, A. Joubert, A.-M. Charvet, F. Esteve, J.-F. Le Bas, H. Elleaume, and J. Balosso Sensitivity variation of doped Fricke gel irradiated with monochromatic synchrotron X rays between 33.5 and 80 keV Radiat Prot Dosimetry, December 1, 2005; 117(4): 425 - 431. [Abstract] [Full Text] [PDF]

				W. Yang, R. F. Barth, G. Wu, M. J. Ciesielski, R. A. Fenstermaker, B. A. Moffat, B. D. Ross, and C. J. Wikstrand Development of a Syngeneic Rat Brain Tumor Model Expressing EGFRvIII and Its Use for Molecular Targeting Studies with Monoclonal Antibody L8A4 Clin. Cancer Res., January 1, 2005; 11(1): 341 - 350. [Abstract] [Full Text] [PDF]